Thermo Fisher Scientific Inc. (TMO): analysis and signal as of September 6, 2026

Published on September 2, 2026 at 17:48 · Updated on September 7, 2026 at 01:09 · by Aurélien Ambert, QDNA

Exchange : NYSE · Sector : Health Technology

In short

The signal is moderate and bearish, with a score of -4. The verdict reflects slowing organic growth and a stretched valuation relative to peers such as DHR and A.

Current signal: moderate (vote 3/3) divergence
Deterministic score: -4.0 → signal expected by the scale : no signal (September 10, 2026)
Layers: fundamentals : positive, price : positive, risks : positive

Triggered rules

Rule	Weight
penalizes an asset whose net debt/EBITDA exceeds the threshold, and the use of leverage (margin/lombard)	-2.5
penalizes a PEG above 2, the anticipated growth is overpaid (overvalued fast grower)	-1.5
penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE	-1.0
moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation)	+0.5
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

Thermo Fisher Scientific Inc. (TMO) shows a solid growth profile with ten consecutive quarters of organic growth and a upward revision to the 2026 guidance, yet the valuation at 25.9x forward earnings exceeds that of peers Danaher and Agilent, and the leverage of 3.6x gross debt to EBITDA represents a constraint in a defensive sector. The share price of 613.78 USD on 04/09/2026 sits close to the 52-week high, below the 650 USD median objective, against a backdrop of complacency in the Cboe regime.

Bull case

Organic growth has delivered ten consecutive quarters, adjusted EPS reported growth reaches 13 %, free cash flow advances by 69 % in the first half of 2026, the repurchase program still has 9 Bn USD remaining, and the 2026 guidance was raised on 23/07/2026 with revenue up 9 % and EPS up 11 %.

Bear case

The forward P/E of 25.9x exceeds Danaher's 23.8x and Agilent's 20.6x, leverage stands at 3.6x gross debt to EBITDA, organic growth of 5 % in Q2 remains below the 5.4 % average, the share price trades close to the 52-week high, and the Cboe regime shows marked complacency with a VIX9D to VIX3M ratio down 32 % and a put to call of 0.76 with a z-score of -1.39.

Scenarios

The bullish scenario, with a 30 % probability, targets 750 USD, the top of the analyst range and a 22 % upside. The central scenario, with a 50 % probability, targets 650 USD, the median objective, or 6 %. The bearish scenario, with a 20 % probability, projects 520 USD, the floor of the range, or -15 %.

Risks

The main risk weighs on the deleveraging trajectory, as a leverage of 3.6x gross debt to EBITDA limits financial flexibility in a defensive sector. A sustained deceleration of organic growth under the 5.4 % average or a contraction of valuation multiples versus peers would amplify pressure on the stock.

Market positioning (short sellers)

Short interest / shares outstanding: 1.29 %
Days to cover: 2.86
Settlement date: 2026-08-14
Source: FINRA (disseminated on 2026-08-26)

Market information published by FINRA (consolidated short interest, all venues), no directional comment.

Upcoming catalysts

Date	Description
October 23, 2026	Q3 2026 results and bioservices / instruments trajectory.

Signal history (last 12 months)

Date	Signal	New fact
September 6, 2026	moderate (3/3)	Analysis unchanged. Personal analysis document, without any recommendation value.
September 2, 2026	moderate (single draw, outside the three-draw protocol)	unchanged
August 31, 2026	moderate (single draw, outside the three-draw protocol)	unchanged

Frequently asked questions

What is the valuation level of Thermo Fisher versus its peers?

The forward P/E reaches 25.9x, above Danaher's 23.8x and Agilent's 20.6x. This valuation premium reflects solid organic growth but exposes the stock to multiple contraction if the dynamic slows or peers recover.

What is the company's debt situation?

Leverage stands at 3.6x gross debt to EBITDA, an elevated level for a defensive sector. This ratio limits financial flexibility and weighs on the overall risk profile, even though the repurchase program still has 9 Bn USD remaining.

How is organic growth evolving?

Organic growth has delivered ten consecutive quarters, but Q2 2026 came in at 5 %, below the 5.4 % historical average. This slight slowdown justifies the cautious signal and calls for monitoring the trajectory before any decision.

What is the current volatility backdrop?

The Cboe regime shows marked complacency, with a VIX9D to VIX3M ratio down 32 % and a put to call of 0.76 with a z-score of -1.39. This low-volatility backdrop can precede a reversal and amplifies the risk of correction.

Sources

The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

July 31, 2026 — 10-Q (SEC · 10-Q)
July 23, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
May 26, 2026 — 5.07 Submission of Matters to a Vote of Security Holders (SEC · 8-K)
May 1, 2026 — 10-Q (SEC · 10-Q)
April 23, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 6, 2026; this page was completed on September 7, 2026 at 01:09 (UTC).
Interests: no position in the stock analysed (TMO) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.